Which is a common result of treating an AIDS patient with zidovudine?

Zidovudine, an antiretroviral medication used to treat HIV/AIDS, is known to have several side effects, one of which is macrocytic anemia. This type of anemia is characterized by the presence of large red blood cells and is often caused by the drug's interference with the production of red blood cells in the bone marrow. Zidovudine affects erythropoiesis, which can lead to decreased levels of hemoglobin and hematocrit, hallmarks of macrocytic anemia.

In the context of AIDS treatment, monitoring the complete blood count (CBC) is critical, as the development of anemia can significantly affect the patient's quality of life and overall treatment outcomes. Recognizing macrocytic anemia early allows for timely interventions, which could include dose adjustments or the use of supportive therapies, such as folic acid supplementation.

Understanding this connection between zidovudine and macrocytic anemia is essential for healthcare professionals managing patients with HIV/AIDS, as it can directly impact treatment plans and patient compliance.